Page 2,601«..1020..2,6002,6012,6022,603..2,6102,620..»

bluebird bio is awarded $9.3m to support its gene therapy treatments

Posted: October 28, 2012 at 6:43 am

By Chris Reidy, Globe Staff

bluebird bio, a Cambridge company that eschews capital letters, said in a Friday press release that the California Institute for Regenerative Medicine has approved a $9.3 million award to support the development one of bluebird bios gene therapies.

The award will support the testing of a gene therapy called LentiGlobin, said the company, which also has an office in San Francisco.

LentiGlobin is designed to treat beta-thalassemia, an inherited blood disorder that causes the body to have an inadequate amount of functional hemoglobin; in its most severe form, patients typically require life-long monthly supportive red blood cell transfusions to treat their severe anemia, according to bluebird bios website.

According to bluebird bio, LentiGlobin is a one-time transformative gene therapy for patients with beta-thalassemia.

The California Institute for Regenerative Medicine was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure provided $3 billion in funding for stem cell research.

Read the original post:
bluebird bio is awarded $9.3m to support its gene therapy treatments

Posted in Gene therapy | Comments Off on bluebird bio is awarded $9.3m to support its gene therapy treatments

New gene therapy method tested in human cells … and it works, researchers report

Posted: October 28, 2012 at 6:43 am

ScienceDaily (Oct. 24, 2012) Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.

The research results are online Oct. 24, in the journal Nature. Dr. Mitalipov also will present the results of his research at the American Society for Reproductive Medicine Conference in San Diego Oct. 24

The OHSU gene therapy method was initially devised through research in nonhuman primates led by Shoukhrat Mitalipov, Ph.D., associate scientist in the Division of Reproductive & Developmental Sciences at ONPRC, Oregon Stem Cell Center and OHSU School of Medicine departments of Obstetrics and Gynecology and Molecular and Medical Genetics.

The procedure was specifically developed to prevent diseases related to gene defects in the cell mitochondria. Mitalipov's previous work was published in the August 2009 edition of Nature. In the current study, Mitalipov, in collaboration with Paula Amato, M.D., associate professor of obstetrics and gynecology in the OHSU Center for Women's Health, demonstrated efficacy of this therapy in human gametes and embryos.

"Cell mitochondria contain genetic material just like the cell nucleus and these genes are passed from mother to infant," explained Mitalipov. "When certain mutations in mitochondrial DNA are present, a child can be born with severe conditions, including diabetes, deafness, eye disorders, gastrointestinal disorders, heart disease, dementia and several other neurological diseases. Because mitochondrial-based genetic diseases are passed from one generation to the next, the risk of disease is often quite clear. The goal of this research is to develop a therapy to prevent transmission of these disease-causing gene mutations."

To conduct this research, Mitalipov and his colleagues obtained 106 human egg cells from study volunteers recruited through OHSU's Division of Fertility and Reproductive Endocrinology. The researchers then used a method developed in previous nonhuman primate studies, to transfer the nucleus from one cell to another. In effect, the researchers "swapped out" the cell cytoplasm, which contains the mitochondria. The egg cells were then fertilized to determine whether the transfer was a success and whether the cells developed normally. Upon inspection, it was demonstrated that it was possible to successfully replace mitochondrial DNA using this method.

"Using this process, we have shown that mutated DNA from the mitochondria can be replaced with healthy copies in human cells," explained Mitalipov. "While the human cells in our study were allowed to develop to the embryonic stem cell stage, this research shows that this gene therapy method may well be a viable alternative for preventing devastating diseases passed from mother to infant."

The current Nature paper also expanded upon the previously reported nonhuman primate work by demonstrating that the method was possible using frozen egg cells. Mitochondria were replaced in a frozen/thawed monkey egg cell, resulting in the birth of a healthy baby monkey named Chrysta.

The second portion of the study, which was completed at ONPRC, is also considered an important achievement because egg cells only remain viable for a short period of time after they are harvested from a donor. Therefore, for this therapy to be a viable option in the clinic, preservation through freezing likely is necessary so that both the donor cell and a mother's cell are viable at the time of the procedure.

While this form of therapy has yet to be approved in the United States, the United Kingdom is seriously considering its use for treating human patients at risk for mitochondria-based disease. It's believed that this most recent breakthrough, combined with earlier animal studies, will help inform that decision-making process.

See the original post here:
New gene therapy method tested in human cells ... and it works, researchers report

Posted in Gene therapy | Comments Off on New gene therapy method tested in human cells … and it works, researchers report

OHSU researchers test new gene therapy method in human cells… and it works

Posted: October 28, 2012 at 6:43 am

Public release date: 24-Oct-2012 [ | E-mail | Share ]

Contact: Jim Newman newmanj@ohsu.edu 503-494-8231 Oregon Health & Science University

PORTLAND, Ore. - Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.

The research results are online Wednesday, Oct. 24, in the highly respected journal Nature. Dr. Mitalipov also will present the results of his research at the American Society for Reproductive Medicine Conference in San Diego Oct. 24'.

The OHSU gene therapy method was initially devised through research in nonhuman primates led by Shoukhrat Mitalipov, Ph.D., associate scientist in the Division of Reproductive & Developmental Sciences at ONPRC, Oregon Stem Cell Center and OHSU School of Medicine departments of Obstetrics and Gynecology and Molecular and Medical Genetics.

The procedure was specifically developed to prevent diseases related to gene defects in the cell mitochondria. Mitalipov's previous work was published in the August 2009 edition of Nature. In the current study, Mitalipov, in collaboration with Paula Amato, M.D., associate professor of obstetrics and gynecology in the OHSU Center for Women's Health, demonstrated efficacy of this therapy in human gametes and embryos.

"Cell mitochondria contain genetic material just like the cell nucleus and these genes are passed from mother to infant," explained Mitalipov. "When certain mutations in mitochondrial DNA are present, a child can be born with severe conditions, including diabetes, deafness, eye disorders, gastrointestinal disorders, heart disease, dementia and several other neurological diseases. Because mitochondrial-based genetic diseases are passed from one generation to the next, the risk of disease is often quite clear. The goal of this research is to develop a therapy to prevent transmission of these disease-causing gene mutations."

To conduct this research, Mitalipov and his colleagues obtained 106 human egg cells from study volunteers recruited through OHSU's Division of Fertility and Reproductive Endocrinology. The researchers then used a method developed in previous nonhuman primate studies, to transfer the nucleus from one cell to another. In effect, the researchers "swapped out" the cell cytoplasm, which contains the mitochondria. The egg cells were then fertilized to determine whether the transfer was a success and whether the cells developed normally. Upon inspection, it was demonstrated that it was possible to successfully replace mitochondrial DNA using this method.

"Using this process, we have shown that mutated DNA from the mitochondria can be replaced with healthy copies in human cells," explained Mitalipov. "While the human cells in our study only allowed to develop to the embryonic stem cell stage, this research shows that this gene therapy method may well be a viable alternative for preventing devastating diseases passed from mother to infant."

The current Nature paper also expanded upon the previously reported nonhuman primate work by demonstrating that the method was possible using frozen egg cells. Mitochondria were replaced in a frozen/thawed monkey egg cell, resulting in the birth of a healthy baby monkey named Chrysta.

See the original post:
OHSU researchers test new gene therapy method in human cells... and it works

Posted in Gene therapy | Comments Off on OHSU researchers test new gene therapy method in human cells… and it works

A first: Stem cell therapy cures HIV patient in Germany

Posted: October 28, 2012 at 6:42 am

By Philip C. Tubeza Philippine Daily Inquirer

Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday.

Dr. Gerald Belimac, program manager of the DOH National AIDS/Sexually Transmitted Infection Prevention and Control Program, said American Timothy R. Brown, the so-called Berlin Patient who had been infected with the human immunodeficiency virus, was cured after getting stem cells in 2007 from a donor who was genetically resistant to the virus that caused AIDS.

However, he said that this procedure was very complex and was still under study.

It takes the right person, the right recipient, the right donor, for a stem cell transplantation particularly on HIV to be successful, Belimac said.

If it comes from other donors, there is really a high chance that the recipient would reject it, she added.

Brown was infected with HIV in 1995 and was later diagnosed with leukemia, or cancer of the blood.

He underwent a transplant of stem cells for the leukemia and it turned out that those stem cells had genes that were resistant to HIV, Belimac said.

Medical research has shown that almost 5 percent of Caucasians are genetically resistant to HIV, he said, but there are still no studies showing Filipinos having similar genes.

Read more here:
A first: Stem cell therapy cures HIV patient in Germany

Posted in Cell Therapy | Comments Off on A first: Stem cell therapy cures HIV patient in Germany

Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

Posted: October 28, 2012 at 6:42 am

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) today announced two independent investigator-sponsored and funded cell therapy clinical studies in Japan have been approved by the Ministry of Health, Labor and Welfare under the Guidelines on Clinical Research Using Human Stem Cells. One study will investigate the use of Cytoris cell therapy as a treatment for ischemic heart failure and the other as a treatment for cirrhosis of the liver. The studies will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate School of Medicine at Kanazawa University Hospital School of Medicine.

In each study, patients will receive an injection of Cytoris cell therapy, which consists of their own adipose-derived stem and regenerative cells (ADRCs) processed at the point-of-care using the Cytoris proprietary and automated Celution System. The ischemic heart failure study will enroll patients with low left ventricular function due to a prior heart attack and the ADRCs will be delivered through the coronary artery. In the study of patients with cirrhosis of the liver, the ADRCs will be delivered through the hepatic artery.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Originally posted here:
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

Posted in Cell Therapy | Comments Off on Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering …

Posted: October 28, 2012 at 6:41 am

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics, Inc. (CYTX) will give a company presentation at the 2012 Stem Cell Meeting on the Mesas Investor and Partnering Forum on Tuesday, October 30.

The following are specific details regarding Cytoris presentation at the conference:

1:45pm PT

The presentation will be recorded and will be available on the Webcasts page of the Cytoris investor relations site the week following the conference.

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industrys most exciting technologies.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

The rest is here:
Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering ...

Posted in Cell Medicine | Comments Off on Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering …

bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy …

Posted: October 28, 2012 at 6:41 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $9.3 million for the first round of its new Strategic Partnership Awards initiative. The award is to support a Phase 1/2 study to evaluate the safety and efficacy of LentiGlobin, the companys development-stage program for the treatment of beta-thalassemia, which will be initiated in the United States in 2013.

We are very encouraged by the clinical data generated to date demonstrating the potential of LentiGlobin as a one-time transformative gene therapy for patients with beta-thalassemia, said David Davidson, M.D., chief medical officer, bluebird bio. bluebird bio has made significant advances in lentiviral vector design, transduction efficiency, and in our manufacturing process, enabling the production of gene-modified products that can be scaled and deployed for many different clinical indications. We are delighted that CIRM has chosen to recognize the importance of this innovative approach for the treatment of one of the most commonly inherited blood disorders, and we are excited to work with CIRM to continue the development of LentiGlobin in the U.S.

bluebird bios LentiGlobin product introduces a fully functional human beta-globin gene into the patient's own hematopoietic stem cells. These corrected stem cells ultimately produce fully functioning red blood cells. bluebird bio is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in the treatment of beta-thalassemia and sickle cell disease. Results of the first patient were reported in Nature in 2010, showing dramatic results, including stable expression of functional beta-globin resulting in transfusion independence which now extends for greater than four years following a single treatment.

This CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and to increase outside investment in CIRM-funded stem cell research. The funding awards were made at the October 25, 2012 meeting of the stem cell agencys governing board, the Independent Citizens Oversight Committee (ICOC).

About CIRM

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bios product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The companys novel approach uses stem cells harvested from the patients own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bios approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patients own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease. Led by a world-class team, its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit http://www.bluebirdbio.com.

Excerpt from:
bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy ...

Posted in Cell Medicine | Comments Off on bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy …

StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

Posted: October 28, 2012 at 6:41 am

NEWARK, Calif., Oct. 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 2nd Annual Investor and Partnering Forum during the 2012 Stem Cell Meeting on the Mesa to be held October 29 -31. Mr. McGlynn is scheduled to speak at 10:15 a.m. Pacific Time on Tuesday, October 30, at the Sanford Consortium for Regenerative Medicine in La Jolla, California.

The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM) and the Alliance for Regenerative Medicine (ARM). The goal of the conference is to bring together the scientific research and business development communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by leading scientists and researchers, as well as an Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings, furthering the translation of clinical research.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and in its subsequent reports on Forms 10-Q and 8-K.

Read the original here:
StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum

Posted in Cell Medicine | Comments Off on StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

Posted: October 28, 2012 at 6:41 am

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present at the 2012 Stem Cell Meeting on the Mesas Investor and Partnering Forum, Oct. 29 and 30 in La Jolla, California.

In his presentation, Mr. Rabin will provide an overview of ACTs ocular programs. The presentation will be webcast by theAlliance for Regenerative Medicinein the weeks following the conference.

The following are specific details regarding ACTs presentation at the conference:

About the Stem Cell Meeting on the Mesas Investor and Partnering Forum

The Investor and Partnering Forum is being organized by the Sanford Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit http://www.stemcellmeetingonthemesa.com.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read more here:
Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

Posted in Cell Medicine | Comments Off on Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

Executive Medicine of Texas Steps into Forefront of Skin Care with International Stem Cell Corporation’s Breakthrough …

Posted: October 28, 2012 at 6:41 am

Top doctors in Texas ink deal to distribute the only skincare line based on human parthenogenetic stem cells.

Dallas, TX (PRWEB) October 25, 2012

Top executives from around the world fly in to meet with Drs. Walter Gaman and Mark Anderson of Executive Medicine of Texas for their innovative and pro-active approach to health care. Voted Best Doctors in Texas by Newsweek Magazine in 2010 and co-authors of the book, Stay Young: 10 Proven Steps to Ultimate Health, the doctors pride themselves on keeping up with the latest technology and weeding out the fads from the real science based products and services.

Dr. Anderson, We are approached almost daily to endorse or support a product. We have no interest in 99.9% of what is brought to us. The irony of Lifeline is that we sought them out.

The duo, who also co-host a nationally syndicated weekly radio program called, The Staying Young Show, with clinical researcher and co-author, Judy Gaman, were first introduced to the Lifeline product when Dr. Elizabeth Hale, a prominent New York dermatologist was a guest on their show and shared her experience with the cream. Once Judy tried it, she and the physicians at Executive Medicine of Texas all agreed that this was nothing short of a miracle cream because Judys skin was changing on a daily basis. It was that personal experience which led the physicians to contact Lifeline and build a relationship.

Donna Queen, President of Lifeline Skin Care adds, Were excited to be working with Dr. Anderson and Dr. Gaman and the Staying Young Show. They have a great understanding of anti-aging medicine, and are established expertslocally, nationally and internationally--on new and innovative treatments for health and wellness.

The unique, patent pending combination of stem cell extracts, vitamins and antioxidants were formulated by a team of ISCOs research scientists in collaboration with cosmetic formulation experts. The serums have been safety tested by independent laboratories, and have been shown to promote firmer, smoother, healthier and younger-looking skin.

Lifeline Skin Care offers consumers the latest advances in biotechnology. These products are game-changers for anti-aging, says Simon Craw, stem cell scientist, International Stem Cell Corporation has developed ethical, potent stem cells that have proved to be a remarkable treatment for aging skin, and we are hopeful these stem cells will someday treat diseases such as Parkinsons disease and diabetes. Today, however, these stem cell extracts are being successfully used for skin rejuvenation. We are reinvesting the profits from the skin care into our research efforts.

Judy Gaman adds, My headshot from less than a year ago doesnt even look like me anymore. If you place that headshot and my new one side by side, it looks like I have turned back the clock ten years. And thats only after using the stem cell cream for six weeks.

The Lifeline collection currently offers two serums, one for day and one for nighttime use, the Defensive Day Moisture Serum SPF 15 and Recovery Night Moisture Serum. In November of 2012 they will launch a multifunctional eye treatment to minimize puffiness and dark circles as well as enhance the firmness of the eye area.

Go here to see the original:
Executive Medicine of Texas Steps into Forefront of Skin Care with International Stem Cell Corporation’s Breakthrough ...

Posted in Cell Medicine | Comments Off on Executive Medicine of Texas Steps into Forefront of Skin Care with International Stem Cell Corporation’s Breakthrough …

Page 2,601«..1020..2,6002,6012,6022,603..2,6102,620..»